GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Factbox-Which Global Business Leaders Met With Chinese President Xi Jinping?
Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...
With 23andMe filing for bankruptcy, what happens to consumers’ genetic data?
Direct-to-consumer genetic testing services carry considerable privacy risks, as the bankruptcy filing of Cailfornia-based ...
NOSH22h
CPG Week: The Insurgent Brands Playbook
The CPG Week podcast team discusses Bain & Company’s Insurgent Brands class of 2025, the similarities among new insurgent ...
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
CSP Daily News18h
2025 Beverage Report: C-Stores Fight for Price-Conscious Consumers
Convenience-store retailers, EV experts talk about the need for urban chargers, vehicle-to-charging-port ratios, higher ...